Abstract:Cutaneous and Oral Squamous Cell Carcinoma (SCC) is the second most common skin and most common mucosal cancers, respectively. A subset of head and neck SCC are at high-risk of local recurrence or developing metastases. The prognosis of patients with metastatic and recurrent HNSCC is poor, with a median survival rate of less than 12-months in many instances. The immune system plays a critical role in the control of many malignancies including SCC. Recent clinical trials with immune checkpoint inhibitors (ICI) demonstrate response in 47% of patients with advanced cutaneous SCC (cSCC) but only 19% in patients with advanced oral SCC (oSCC). In this study we used high-dimensional imaging mass cytometry to examine up to 40 parameters to compare the tumor microenvironment of cSCC and oSCC. In cSCC we discovered that patient tumors contained immune signatures and individual cell interactions that link progression to immune status in patients absent of clinical immune suppression (ACIS). There were significant differences in the CD4+, CD8+ T cell and leukocyte immune composition of primary tumors that never progressed compared to primary tumors from DP patients ACIS. We also found significant spatial differences in primary tumors from these patients including cell-interactions and specific regions present in the TME landscape. Cellular regional analysis of the TME showed squamous cell-enriched tumor regions associated with DP tumors. In oSCC, patients who did not respond to ICI showed significantly higher infiltrates of proliferating CD4+ Regulatory T cells (Tregs). NK cells and Central Memory Cytotoxic T cells were found to be significantly higher in patients who responded to therapy. Furthermore, we identified key spatial interactions including a subset of Tregs significantly interacting with specific PMN-myeloid derived suppressor cells (MDSC) in patients who failed to respond to PD-1 ICI. Interestingly, these Tregs and PMN-MDSCs were found to significantly avoid each other in the TME of patients who responded to PD-1 ICI. Mapping the immune landscape of human tumors could provide insight into the role of immune cells in disease progression and response and resistance to therapy. The findings of this research offers a clear pathway to determine clinical outcomes based on a patients TME signature. Citation Format: Angela L. Ferguson, Thomas Beddow, Ashleigh Sharman, Ruth O. Allen, Thomas Ye, Jenny Lee, Tsu-Hui (Hubert) Low, Sydney Ch'ng, Carsten Palme, Bruce Ashford, Marie Ranson, Michael Elliot, Jonathan R. Clark, Ellis Patrick, Umaimainthan Palendira, Ruta Gupta. High-dimensional spatial analysis of the tumor-microenvironment to determine metastatic disease progression and response and resistance to therapy in head and neck cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl) nr PR12.

Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma – a DAHANCA 19 study

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC

Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG

Tumor microenvironment in head and neck squamous cell carcinomas: Predictive value and clinical relevance of hypoxic markers. A review

Hypoxic gene expression is a prognostic factor for disease free survival in a cohort of locally advanced squamous cell cancer of the uterine cervix

Multiparametric functional MRI and 18F-FDG-PET for survival prediction in patients with head and neck squamous cell carcinoma treated with (chemo)radiation

Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma

Type I conventional dendritic cells and CD8+ T cells predict favorable clinical outcome of head and neck squamous cell carcinoma patients

The Prognostication of Surgically Resected Head and Neck Squamous Cell Carcinoma Using Pre‐Therapy Neutrophil and Lymphocyte Counts

Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma

Prognostic value of pretreatment radiological MRI variables and dynamic contrast-enhanced MRI on radiotherapy treatment outcome in laryngeal and hypopharyngeal tumors

Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re-radiotherapy

Circulating p16-Positive and p16-Negative Tumor Cells Serve as Independent Prognostic Indicators of Survival in Patients with Head and Neck Squamous Cell Carcinomas

Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma

The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients (R/M).

Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy

Abstract PR12: High-dimensional spatial analysis of the tumor-microenvironment to determine metastatic disease progression and response and resistance to therapy in head and neck cancer

Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models

Novel markers for poor prognosis in head and neck cancer